Integrated Approach Facilitates Inhalation Drug Development

In this month’s Pharmaceutical Technology magazine, Vectura’s Sara Sefton, Fergus Manford, Tim Gardner and Andrew Walker feature in a three-page article focusing on our DPI expertise, headlined: ‘Integrated approach facilitates inhalation drug development.’

“DPIs are generally small and portable, do not require use of expensive propellants, and can be relatively simple devices, which can result in lower manufacturing costs,” they report.

“The development and manufacturing of DPI products is complex, and close integration between formulation, device development, analytical, and manufacturing teams can help overcome challenges and shorten timelines, reducing the risk of expensive and time-consuming changes later in development.”

The piece then goes on to examine device selection factors, particle engineering and formulation, and sizing up appropriate scale-up throughout the product development process.

You can read the article ‘Integrated approach facilitates inhalation drug development.’ here.